Survodutide

Volume Pricing

Price per pack (10 vials). Discount applies to this compound only – no mix and match.

Survodutide — Dual GCGR/GLP-1R Agonist

Survodutide (development code BI 456906) is a synthetic dual agonist targeting the glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R), co-developed by Boehringer Ingelheim and Zealand Pharma. It emerged from research programs exploring the complementary metabolic roles of glucagon and GLP-1 signaling in the liver and pancreas. Phase II clinical data published in 2023–2024 examined its effects in obesity and metabolic dysfunction-associated steatohepatitis (MASH). Unlike pure GLP-1R agonists such as semaglutide, survodutide’s GCGR component adds a hepatic fat oxidation and lipolytic dimension that has shown more pronounced visceral and hepatic fat reduction in preclinical and early clinical models. The molecule represents a mechanistic step beyond single-receptor incretin pharmacology.

Why Survodutide’s Dual-Receptor Pharmacology Matters

GLP-1R agonism alone drives satiety and insulin secretion; GCGR agonism independently promotes hepatic fat oxidation and gluconeogenesis regulation. In combination, these pathways produce an additive reduction in body weight and liver fat accumulation that neither target achieves as efficiently in isolation. Survodutide’s specific GCGR:GLP-1R binding ratio has been tuned to minimize the hyperglycemic risk that full glucagon agonism would otherwise introduce, making it a pharmacologically balanced dual-receptor tool compound for metabolic research.

Research Applications

Survodutide is used in studies examining:

• Dual incretin receptor pharmacology and receptor occupancy modeling
• Metabolic dysfunction-associated steatohepatitis (MASH/NASH) pathology
• Visceral adiposity reduction mechanisms in diet-induced obesity models
• Hepatic lipid metabolism and fatty acid oxidation pathway regulation
• GLP-1R vs. GCGR contribution to weight reduction in comparative receptor studies
• Metabolic syndrome models requiring combined hepatic and glycemic endpoint assessment

Specifications

Reconstitution

Survodutide arrives as lyophilized powder and must be reconstituted with bacteriostatic water prior to use. Use the formula:

Total mg ÷ Volume added (mL) = Concentration (mg/mL)

Example: 10mg vial + 2mL BAC water = 5mg/mL solution

Reconstituted peptide should be stored at 2–8°C and used within 28–30 days.

Protocol Notes

Research frameworks for survodutide are drawn from published Phase II clinical protocols and preclinical dose-escalation studies. Human trials used a weekly subcutaneous dose-escalation design; animal studies employed weight-based subcutaneous dosing.

• Dose range (clinical literature): 0.3mg escalating to 6mg SC weekly (Phase II obesity and MASH trials)
• Dose range (preclinical literature): 1–10 nmol/kg in rodent and non-human primate models
• Frequency: Once weekly in clinical protocols; daily or twice-weekly in rodent studies
• Study duration: 26–46 weeks in Phase II human trials; 4–12 weeks in rodent efficacy studies

Research Stacks

Survodutide is commonly paired in research settings with:

• Semaglutide — Semaglutide is a selective GLP-1 receptor agonist; pairing with Survodutide’s GLP-1/glucagon dual agonism allows researchers to isolate the incremental contribution of glucagon receptor engagement to outcomes observed with GLP-1 signaling alone.
• Tirzepatide — Tirzepatide co-activates GLP-1 and GIP receptors; combined with Survodutide’s GLP-1/glucagon profile, the pairing enables comparative studies of GIP versus glucagon receptor contributions to incretin-driven metabolic regulation.
• CJC-1295 No DAC / Ipamorelin — CJC-1295 No DAC and Ipamorelin stimulate GH secretion via GHRH and GHS-R1a; pairing with Survodutide is used to examine whether GH axis activation interacts with dual GLP-1/glucagon receptor engagement in metabolic research models.

Purity Guarantee

Every batch is ≥99% purity. If you independently test your compound and the results don’t match — send us the COA and we’ll issue store credit, no questions asked.